Clinerion Partners With Volv Global to Bring Treatment Earlier to Patients By Enhancing Diagnosis Search on Patient Network Explorer with inTrigue AI Algorithms

BASEL, Switzerland, September 11, 2019 /PRNewswire-PRWeb/ — The partnership between Clinerion and Volv Global brings benefits to patients by combining Volv’s uniquely accurate cohort identification algorithms with Clinerion’s growing data network of hospitals around the world. The Volv and Clinerion partnership will deploy Volv’s inTrigue algorithms across many more hospitals and this will create tangible outcomes for patients who suffer from late diagnosis of between seven and 15 years, as well as from misdiagnosis and subsequent increased disease burden.

Volv’s inTrigue toolset offers enhanced clinical trial cohort selection and patient modeling for earlier diagnosis of rare and difficult to diagnose diseases. This supports rare disease communities who wish to be able to deploy effective early diagnostic signaling tools to help patients get earlier referral and confirmatory diagnosis.

Clinerion’s Patient Network Explorer leverages patient electronic health record (EHR) data to offer data intelligence for the acceleration of drug development, bringing innovative drugs earlier to patients. PNEx performs real-time patient data analytics on electronic medical records from Clinerion’s network of connected hospitals to offer solutions for clinical trial patient recruitment and generate data for real-world evidence. This process accelerates recruitment, the most prominent reason for trial delays, which result in avoidable suffering of patients and cost pharmaceutical companies sales revenues.

“Our partnership brings direct benefits to patients by combining Volv’s uniquely accurate cohort identification algorithms with Clinerion’s rapidly growing data network of hospitals around the world,” says Christopher Rudolf, CEO of Volv. “We can jointly offer a wider reach for earlier diagnosis of rare diseases and enhanced clinical trial cohort selection through the inTrigue toolset and Clinerion’s PNEx.”

“AI integration is the next crucial step in the development of Patient Network Explorer,” says Ian Rentsch, Clinerion CEO. “Volv’s technologies will support us in harnessing the full power of the patient data in our hospital partners’ databases, to the betterment of patient outcomes throughout our network.”

Clinerion and Volv Global will launch their partnership at a special event at the Intelligent Health AI conference on September 11th-12th, in Basel, Switzerland. Please contact the press officers below if you would like to interview representatives of the two companies.

About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion Website:

Clinerion’s Patient Network Explorer:

For more information, please contact:
Le Vin Chin
Director, Head of Marketing & Communications
Clinerion Ltd
Elisabethenanlage 11, 4051 Basel, Switzerland
Tel.: +41 61 865 60 54

About Volv Global SA
Volv is a Swiss is an AI and applied data science company based in Lausanne that produces solutions to address key critical issues in Healthcare for today and tomorrow. We develop differentiated Artificial Intelligence methodologies addressing a defined set of problems in healthcare, and have solutions that are targeted on rare diseases, personalised medicines and difficult-to-diagnose diseases with the product inTrigue. We also focus on cognitive disorders with inCognita, and are working on breakthrough management solutions for anti-microbial resistance and personalised oncology.

With unique tools, including some that are focused on finding weak signals in sparse, unstructured and structured data, Volv has a unique position in the Artificial Intelligence landscape. This allows us to focus on tangible economic and healthcare outcomes by differentiating patient cohorts and symptoms in a novel way that is required for the next generation of healthcare and the change in population dynamics that we see evolving. Volv’s toolsets are repeatable solutions that can fit into any data environment and allow rapid return on investment for our customers, building to longer term strategic partnerships.
Volv Global website:

For more information, please contact:
Jan Prins
Business Officer
Volv Global SA, Digital Health Hub, Building SE-A, Route de la Corniche 3, 1066 Epalinges, Switzerland
Tel.: +41 79 739 37 05


SOURCE Clinerion Ltd.

Artificial Intelligence News

  • Adobe Expands Integrations With AI-Drive Account Profiling, LinkedIn Synching

    Adobe has launched new capabilities within the Marketo Engage ABM Essentials offering, part of the Adobe Marketing Cloud, including new AI-powered models in its Account Profiling tool and an expanded LinkedIn partnership. The two updates aim to help accelerate the execution of ABM strategies for sales and marketing teams, as well…(read more...)

  • NLG in the newsroom: fast, consistent, and hyperlocal

    NLG in the newsroom: fast, consistent, and hyperlocal We’ve written about how Natural Language Generation can eliminate the bottleneck of manual, one-at-a-time analysis within business environments, producing data-driven insights that otherwise would remain fossilized in spreadsheets on the network drive. It is also worth noting that the same principles apply…(read more...)

  • Twilio: Harnessing The Power Of AI (Artificial Intelligence)

    Twilio, a provider of voice, video and messaging services, reported its second quarter results and they were certainly standout. Revenues spiked by 86% to $275 million and there was a profit of 2 cents a share. On the earnings call, CEO Jeff Lawson noted: “We have the opportunity to change…(read more...)